In a move to help clients ensure the quality and validity of their clinical trial results, WCG has purchased Intrinsic Imaging, a global provider of medical imaging core lab services.

The company is a seasoned, ISO-certified provider of full-service medical imaging, with more than a decade of experience supporting drug, device and AI clinical trials and a team that features more than 500 board-certified, fellowship-trained physicians and key opinion leaders. The Intrinsic team covers all therapeutic areas, including but not limited to AI software, cardiology, central nervous system, gastroenterology, interventional medical devices, musculoskeletal, oncology and ophthalmology.

Intrinsic has been certified by the British Standards Institute and is also the only organization in the world to hold five ISO certifications specifically for conducting imaging core lab services for clinical trials.

“The growing need to visually demonstrate safety and efficacy to regulators, patients, providers, payers and other research stakeholders is driving the increasingly critical role medical imaging is playing in clinical trials,” said Donald Deieso, executive chairman and CEO of WCG.